Amgen Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Amgen Inc. stock analysis AMGN overview
Slightly Bullish +25

Top Stock Reports for Roche, AT&T & Amgen - Yahoo Finance

🔬 Roche (RHHBY) shares rose 10% over six months, driven by strong sales of key products like Ocrevus and Vabysmo.

⚠️ Roche faces challenges from declining legacy drug revenues due to biosimilar competition and unfavorable foreign-exchange rates.

💊 Amgen (AMGN) shares jumped 18.5% in the same period, fueled by growth in medicines like Evenity and Repatha offsetting oncology decline.

⚖️ Amgen anticipates significant sales erosion for Prolia and Xgeva starting in 2026 due to biosimilar launches in 2025.

📡 AT&T (T) outperformed the industry with an 8% gain, supported by healthy momentum in postpaid wireless and lower churn rates.

💼 AT&T plans to expand market reach through the acquisition of Lumen's fiber internet connectivity business.

📉 Linear TV subscriber declines remain a risk factor for AT&T amidst fierce U.S. wireless competition and margin pressures.

🏢 Marsh & McLennan (MRSH) expanded geographically through acquisitions but faces concerns over escalating expenses.

⚡ Entergy Corp (ETR) plans to invest $43 billion from 2026-2029 and add 14-17 GW of renewables by 2031.

🔍 IDEXX Laboratories (IDXX) benefits from strong growth in CAG Diagnostics but carries a worrisome high debt burden.

🚛 Waste Connections (WCN) shows rising revenue per employee reflecting productivity gains despite a current ratio below industry average.

⚙️ PG&E Corporation (PCG) is investing in grid reliability and battery energy storage to support clean energy growth.

🏦 Citizens Financial (CFG) maintains organic growth driven by strong net interest margins despite rising operational costs.

📅 This research daily was published by Zacks Research on Monday, March 30, 2026, ahead of Wall Street trading.

💰 Amgen's pipeline focuses heavily on its obesity candidate MariTide amidst pricing headwinds and competitive pressure.

⚙️ Roche is actively seeking acquisitions to diversify its portfolio following the expiration or decline of major patent protections.

📡 AT&T aims to gain a competitive edge through edge computing services for businesses routing application-specific traffic.

Bullish Signals
  • Amgen's shares have significantly outperformed the industry over the past six months with a +18.5% return, far exceeding the sector's +9.1% gain.
  • Key medicines including Evenity, Repatha, Uplizna, and newer assets like Imdelltra and Tezspire are driving sales growth.
  • New biosimilar launches are contributing to top-line growth rather than detracting from it.
  • The company has several key pipeline assets in development with a primary focus on the obesity candidate MariTide.
Risk Factors
  • Amgen faces significant sales erosion for best-selling drugs Prolia and Xgeva in 2026 due to biosimilar launches occurring in 2025.
  • Increased pricing headwinds and competitive pressure are negatively impacting the sales of many of Amgen's existing products despite new drug growth.
  • Pipeline setbacks and the upcoming loss-of-exclusivity (LOE) cliff pose concerns for the company's future revenue trajectory.
  • Roche's performance is weighed down by unfavorable foreign-exchange movements as weakness in the U.S. dollar adversely impacts international sales.
  • At&T faces fierce competition in the U.S. wireless market which necessitates discounts and cash credits, escalating margin pressures.
  • AT&T is experiencing a steady decline in linear TV subscribers and legacy services despite momentum in its wireless business.
  • Roche is looking to diversify through acquisitions specifically due to declining sales from legacy drugs Avastin, Herceptin, MabThera, and Actemra driven by biosimilar competition.
Full Analysis
Yahoo Finance hosts a comprehensive summary of Zacks Research Daily reports focusing on Amgen alongside Roche and AT&T, providing an in-depth analysis of AMGN alongside other major stocks. The article details that Amgen's shares have outperformed the Zacks Medical - Biomedical and Genetics industry over the past six months, rising 18.5% compared to the sector's 9.1% gain. This performance is primarily driven by strong sales from key medicines such as Evenity, Repatha, and Uplizna, which successfully offset declining revenues from oncology biosimilars and mature products like Enbrel. The report highlights that new medicines including Imdelltra, Tavneos, and Tezspire are also contributing to top-line growth alongside new biosimilar launches. Despite this momentum, the analysis notes significant headwinds for Amgen, including increased pricing pressures and competitive threats hurting sales of many products. Specific concerns include the expected erosion of sales for best-selling drugs Prolia and Xgeva in 2026 due to biosimilar launches scheduled for 2025. The article further emphasizes that pipeline setbacks and the approaching loss-of-exclusivity (LOE) cliff present risks to future revenue streams. Additionally, the company is looking toward its obesity candidate, MariTide, as a key pipeline asset, though it faces ongoing competitive challenges. Beyond Amgen, the article briefly summarizes research on Roche, AT&T, Marsh & McLennan, Entergy, IDEXX, Waste Connections, PG&E, and Citizens Financial. The Zacks analyst team identifies operational performance, strategic acquisitions, infrastructure investments, and organic growth as primary drivers for most of these companies, while flagging issues such as legacy drug declines, margin pressures, debt burdens, and rising expenses as areas of concern.